J&J, Bayer's Xarelto scores FDA nod to treat acutely ill patients during and after hospitalization

14th October 2019 Uncategorised 0

Johnson & Johnson and Bayer’s Xarelto, once king of the warfarin alternative market, is now chasing chasing Eliquis. But with a new approved indication in the books—its eighth—it’s not backing down. The FDA approved Xarelto to help prevent blood clots for acutely ill patients without a high risk of bleeding during and after hospitalization.

More: J&J, Bayer's Xarelto scores FDA nod to treat acutely ill patients during and after hospitalization
Source: fierce